EphA2在人膀胱移行细胞癌中的表达及其临床意义

目的研究EphA2在在人膀胱移行细胞癌中的表达及临床意义。方法选取全膀胱切除后癌旁2.5 cm以上镜下证实为对照组的膀胱黏膜11例,移行细胞癌标本48例,采用免疫组化1二步法,每个石蜡块标本切取5张切片。其中的4片分别用于EphA2、VE-cadherin、K i67作为一抗的研究,另外1片用于HE染色以确定该病例的WHO分级及分期。另外对患者的预后进行随访,随访6~50个月,对复发者与未复发者的EphA2的阳性表达情况进行统计,并对患者术后生存时间进行分析。结果EphA2在膀胱TCC病理G1中的阳性表达率较低,只有14.3%;在G2级中阳性染色达到36.8%;在G3中阳性染色达到66.7%。通过两两比较,差异有显著性（P〈0.01）,而在正常膀胱黏膜组织中都是阴性。结论EphA2过度表达可以促进细胞的增殖,血管形成,可能是通过VE-cadherin而起作用。复发患者的EphA2的阳性表达率明显高于未复发者,可以将其作为评估患者术后是否容易复发的一个指标,EphA2还可能是评估患者术后生存时间的一个指标,并且可能成为肿瘤靶向治疗的新靶点。

Expression and clinical significance of EphA2 in transitional cell carcinoma of human bladder

Objective To investigate the expression and clinical significance of EphA2 in transitional cell carcinoma of human bladder. Methods Eleven specimens of normal mucous membrane of urinary bladder, which were more than 2. 5cm far away from the tumors and were pathologically confirmed after cystectomy, and 48 specimens of bladder transitional cell carcinoma were selected. EphA2, VE-cadherin and Ki67 were analyzed by immunohistochemical technique. Five resections were cut from every paraffin block of specimen. Of them, 4 were used to analyze EphA2, VE-cadherin and Ki67,and another section was used to confirm the clinical stages and pathological grades of WHO after HE staining. The patients were followed up for 6-50 months to evaluate the prognosis. The relationship between EphA2 expression and tumor recurrence was avaluaeted statistically. Survival time after operation was also analyzed. Results The positive expression of EphA2 in pathological G1-3 were 14. 3% ,36. 8% and 66.7%. The differences in expression of EphA2 between G1, G2 and G3 were statistically significant. However, no specimen of normal mucous mem- brane was EphA2 positive. Conclusions The overexpression of EphA2 can accelerate cellular proliferation and angiogenesis through interaction between EphA2 and VE-cadherin. Patients who have tumor recurrence tend to show high EphA2 expression. EphA2 can be a marker for evaluating tumor recurrence and patients＇ survival time after the operation. It may also be an attractive therapy target for bladder cancer.